Safety and Efficacy Implications of Discontinuing Combination Ipilimumab and Nivolumab in Advanced Melanoma

J Clin Oncol. 2017 Dec 1;35(34):3792-3793. doi: 10.1200/JCO.2017.75.2055. Epub 2017 Oct 19.

Authors

Matteo S Carlino¹, Shahneen Sandhu¹

Affiliation

¹ Matteo S. Carlino, Westmead and Blacktown Hospitals and University of Sydney, Sydney, New South Wales, Australia; and Shahneen Sandhu, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Victoria, Australia.

PMID: 29048973
DOI: 10.1200/JCO.2017.75.2055

No abstract available

Publication types

Editorial
Comment

MeSH terms

Humans
Ipilimumab
Melanoma*
Nivolumab
Skin Neoplasms*

Substances

Ipilimumab
Nivolumab